NASDAQ · CAMP
CAMP4 Therapeutics Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CAMP: Nov 5, 2026
CAMP4 Therapeutics Corporation Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.19. The reported EPS for the same quarter last year was $-0.55.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.19 | $-0.14 | $-0.26 | 6 |
| Dec 2026 | $-0.20 | $-0.14 | $-0.31 | 6 |
| Mar 2027 | $-0.18 | $-0.13 | $-0.21 | 4 |
| Jun 2027 | $-0.19 | $-0.14 | $-0.22 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · MarketBeat · RTTNews- Zacks · Oct 29, 9:00 AM EDTCAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseCAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 23, 4:55 PM EDTRaymond James Initiates Coverage of Camp4 Therapeutics with Strong BuyFintel reports that on October 23, 2026, Raymond James initiated coverage of Camp4 Therapeutics (NASDAQGM:CAMP) with a Strong Buy recommendation. CalAmp Corp., based in the United States, operates primarily in the wireless communications industry, delivering comprehensive technol
- MarketBeat · Oct 20, 11:04 AM EDTCAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic DiseaseKorro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length proteins. Speaking during a Chardan panel on RNA medicines, Ram Ai
- MarketBeat · Sep 28, 3:02 PM EDTCAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028. The company’s analyst event focused on CMP-002,
- RTTNews · Sep 10, 9:51 AM EDTCAMP4 Therapeutics Secures UK Authorization For CMP-002 Clinical Trial In SYNGAP1 Disorder(RTTNews) – CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company developing RNA-targeting medicines, announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized inclusion of UK sites in its global Phase 1/2 clinic
- RTTNews · Aug 17, 9:19 AM EDTCAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026(RTTNews) – CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics for genetic diseases, on Friday reported financial results for the second quarter ended June 30, 2026, and provided corporate updates.
- Zacks · Aug 13, 6:50 PM EDTCAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue EstimatesCAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTOcugen (OCGN) Reports Q2 Loss, Beats Revenue EstimatesOcugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 6:10 PM EDTMannKind (MNKD) Reports Q2 Loss, Beats Revenue EstimatesMannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 3, 10:31 PM EDTTop Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum(RTTNews) – Today's top biotech gainers include Universe Pharmaceuticals, which recently filed its SEC report for the six months ended March 31, 2026; Cumberland Pharma, ahead of its second-quarter 2026 financial results due Tuesday; and Autolus Therapeutics, following the releas
- Zacks · Aug 3, 6:45 PM EDTCRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue EstimatesCRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 29, 7:07 AM EDTCAMP4 Gets TGA Nod For Phase 1/2 Evaluating CMP-002 In SYNGAP1; To Gain $50 Mln Milestone Payment(RTTNews) – CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Monday reported receiving clearance from the Australian Therapeutic Goods Administration (TGA) and the Human Research Ethics Committee (HREC) to initiate the Phase 1/2 trial for CMP-
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for CAMP4 Therapeutics Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.